183 related articles for article (PubMed ID: 35282885)
1. Kidney Transplant Recipients Have Higher Malignancy Prevalence Than Hemodialyzed Patients.
Pyrża M; Małyszko J; Głogowski T; Wieliczko M; Żebrowski P; Małyszko J
Transplant Proc; 2022 May; 54(4):972-975. PubMed ID: 35282885
[TBL] [Abstract][Full Text] [Related]
2. Malignancy Prevalence in Waitlisted Potential Kidney Transplant Recipients Is Very Low Relative to Patients After Kidney Transplantation.
Pyrża M; Małyszko J; Żebrowski P; Wieliczko M; Małyszko J
Transplant Proc; 2020 Oct; 52(8):2264-2267. PubMed ID: 32362461
[TBL] [Abstract][Full Text] [Related]
3. Malignancy Prevalence in the Dialyzed Population and in Waitlisted Potential Kidney Transplant Recipients.
Pyrża M; Głogowski T; Wieliczko M; Żebrowski P; Ewa W; Semeniuk-Wojtaś A; Stec R; Nazarewski S; Małyszko J
Transplant Proc; 2022 May; 54(4):930-933. PubMed ID: 35279304
[TBL] [Abstract][Full Text] [Related]
4. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center.
Mihalov ML; Gattuso P; Abraham K; Holmes EW; Reddy V
Clin Transplant; 1996 Jun; 10(3):248-55. PubMed ID: 8826661
[TBL] [Abstract][Full Text] [Related]
5. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.
Boratyńska M; Watorek E; Smolska D; Patrzałek D; Klinger M
Transplant Proc; 2007 Nov; 39(9):2736-9. PubMed ID: 18021973
[TBL] [Abstract][Full Text] [Related]
6. Incidence and management of Kaposi sarcoma in renal transplant recipients: the Greek experience.
Zavos G; Moris D; Vernadakis S; Bokos J; Lionaki S; Mamarelis G; Panagiotellis K; Zavvos V; Boletis I
Transplant Proc; 2014 Nov; 46(9):3199-202. PubMed ID: 25420858
[TBL] [Abstract][Full Text] [Related]
7. Dermatopathology of skin cancer in solid organ transplant recipients.
Stoff B; Salisbury C; Parker D; O'Reilly Zwald F
Transplant Rev (Orlando); 2010 Oct; 24(4):172-89. PubMed ID: 20709518
[TBL] [Abstract][Full Text] [Related]
8. Post-renal transplant malignancies: Opportunities for prevention and early screening.
Turshudzhyan A
Cancer Treat Res Commun; 2021; 26():100283. PubMed ID: 33338850
[TBL] [Abstract][Full Text] [Related]
9. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
[TBL] [Abstract][Full Text] [Related]
10. Posttransplant Lymphoproliferative Disorders in Irish Renal Transplant Recipients: Insights From a National Observational Study.
OʼRegan JA; Prendeville S; McCaughan JA; Traynor C; OʼBrien FJ; Ward FL; OʼDonovan D; Kennedy C; Berzan E; Kinsella S; Williams Y; OʼKelly P; Deady S; Comber H; Leader M; Conlon PJ
Transplantation; 2017 Mar; 101(3):657-663. PubMed ID: 27214265
[TBL] [Abstract][Full Text] [Related]
11. Malignancy risk in kidney transplant recipients exposed to immunosuppression pre-transplant for the treatment of glomerulonephritis.
Massicotte-Azarniouch D; Detwiler RK; Hu Y; Falk RJ; Saha MK; Hogan SL; Derebail VK
Nephrol Dial Transplant; 2023 Aug; 38(9):2009-2018. PubMed ID: 36549661
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and prognosis of post-transplant lymphoproliferative disorders within renal allograft: Report from the PTLD.Int. Survey.
Khedmat H; Taheri S
Ann Transplant; 2010; 15(3):80-6. PubMed ID: 20877272
[TBL] [Abstract][Full Text] [Related]
13. Association Between Declined Offers of Deceased Donor Kidney Allograft and Outcomes in Kidney Transplant Candidates.
Husain SA; King KL; Pastan S; Patzer RE; Cohen DJ; Radhakrishnan J; Mohan S
JAMA Netw Open; 2019 Aug; 2(8):e1910312. PubMed ID: 31469394
[TBL] [Abstract][Full Text] [Related]
14. Course of renal allograft function after diagnosis and treatment of post-transplant lymphoproliferative disorders in pediatric kidney transplant recipients.
Zierhut H; Kanzelmeyer N; Buescher A; Höcker B; Mauz-Körholz C; Tönshoff B; Metzler M; Pohl M; Pape L; Maecker-Kolhoff B
Pediatr Transplant; 2021 Sep; 25(6):e14042. PubMed ID: 34021949
[TBL] [Abstract][Full Text] [Related]
15. Post-transplantation Malignancy After Kidney Transplantation in Turkey.
Keles Y; Tekin S; Duzenli M; Yuksel Y; Yücetin L; Dosemeci L; Sengul A; Demirbaş A; Tuncer M
Transplant Proc; 2015 Jun; 47(5):1418-20. PubMed ID: 26093732
[TBL] [Abstract][Full Text] [Related]
16. Post-transplantation lymphoproliferative disorders in renal vs. simultaneous renal-pancreas allograft recipients: a survey and analysis of data from the literature.
Khedmat H; Taheri S
Saudi J Kidney Dis Transpl; 2013 Jan; 24(1):1-7. PubMed ID: 23354184
[TBL] [Abstract][Full Text] [Related]
17. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
Wasson S; Zafar MN; Best J; Reddy HK
J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
[TBL] [Abstract][Full Text] [Related]
18. Early onset post-transplant lymphoproliferative disease is associated with allograft localization.
Bakker NA; van Imhoff GW; Verschuuren EA; van Son WJ; Homan van der Heide JJ; Veeger NJ; Kluin PM; Kluin-Nelemans HC
Clin Transplant; 2005 Jun; 19(3):327-34. PubMed ID: 15877793
[TBL] [Abstract][Full Text] [Related]
19. Variation in Dialysis Exposure Prior to Nonpreemptive Living Donor Kidney Transplantation in the United States and Its Association With Allograft Outcomes.
Gill JS; Rose C; Joffres Y; Landsberg D; Gill J
Am J Kidney Dis; 2018 May; 71(5):636-647. PubMed ID: 29395484
[TBL] [Abstract][Full Text] [Related]
20. Incidence and Risk Factors of Post-renal Transplantation Malignancies in North of Iran, A 20-year Experience.
Nejatifar F; Monfared A; Khosravi M; Lebadi M; Shakiba M; Mokhtari G; Aghajanzadeh P; Haghdar-Saheli Y; Movasaghi A; Ramezanzadeh E; Akhondzadeh L
Iran J Kidney Dis; 2020 Dec; 14(6):439-447. PubMed ID: 33277447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
